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QUALITY OF LIFE AFTER SUBARACHNOID 
HEMORRHAGE IN RELATION TO RISK 
ESTIMATION BEFORE SURGERY
Tóth KJ1, Szende A2, Contreras M1, Nyáry I1, Futó J1
1National Institute of Neurosurgery, Budapest, Hungary; 
2AstraZeneca, Törökbálint, Hungary
INTRODUCTION: Traditionally, long-term results of
neurosurgical interventions have been measured by the
Glasgow Outcome Scale. However, today, it is increas-
ingly important to assess health related quality of life
(HRQoL) as it is of utmost importance to the patients
and their families. The purpose of our study was to inves-
tigate the relationship between before operation risk esti-
mation and HRQoL one year after operation in patients
operated for cerebral aneurysms within 72 hours after
subarachnoid hemorrhage (SAH). METHODS: 97 pa-
tients underwent intracranial aneurysm surgery in the
National Institute of Neurosurgery in 1998. All patients
received nimodipine p os. The fluid therapy was guided
individually as the clinical signs and multimodal moni-
toring data indicated. The ASA physical status risk esti-
mator was assessed before surgery. 12 months after the
surgery, patients were interviewed by phone or by post.
Health status was measured as mortality and as HRQoL
measured by the EQ-5D questionnaire. ANOVA tests
were conducted. RESULTS: 6 out of the 97 patients were
lost during follow-up. Data of 91 patients (60 females
and 31 males) were finally analyzed. Mortality rate was
25,3%. 68 patients were alive one year after surgery. EQ-
5D weighted health status was 0.82, 0.55, 0.40 for pa-
tients with ASA scores of 1, 2, and 3, respectively (P 
0.021). Patients with ASA scores of 4 or 5 did not sur-
vive. Patients with intracerebral hemorrhage, ICH (25%)
had drastically lower HRQoL, 0.47 versus 0.70 (P 
0.042). CONCLUSION: Our study showed that ASA
risk estimation scores can well predict future HRQoL of
surviving patients. Patients who had an ASA value of 3
lived in worse HRQoL than people over eighty years of
age in the general population. Therefore, our results sug-
gest that pre-operation risk estimators should be care-
fully considered at clinical decisions and at subgroup
analyses in cost-effectiveness studies.
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ECONOMIC EVALUATION OF TRANSDERMAL 
FENTANYL IN THE TREATMENT OF CHRONIC 
NON-CANCER PAIN IN DENMARK
Frei A1, Nuyts G2, Mehnert A2, Gerber D1
1HealthEcon, Basle, Switzerland; 2Janssen Pharmaceutica, 
Beerse, Belgium
OBJECTIVE: This is a cost-effectiveness analysis com-
paring one-year treatment of chronic non-malignant pain
with transdermal fentanyl and with sustained release
morphine. METHODS: A Markov-model was developed
which modeled the treatment as a recursive process of 12
monthly cycles. Effectiveness was defined as days with
good pain control. The following direct medical costs
were included: baseline treatment, breakthrough medica-
tion, concomitant medication and adverse event treat-
ment costs. Data on probabilities for altering pain con-
trol, for contracting adverse events, for switching treatment,
and resource use data were obtained from clinical trials
and from a Delphi panel. Unit costs were derived from
official tariff and price lists. Base-case analysis, one-way
and two-way sensitivity analyses were carried-out. RE-
SULTS: Effectiveness was 99 days with good pain con-
trol for the transdermal fentanyl treatment in compari-
son with 64 days for sustained release morphine. The
cost-effectiveness ratio (cost per day with good pain
control) was Euro 8.54 with transdermal fentanyl and
Euro 7.94 with sustained release morphine. The incre-
mental effectiveness of transdermal fentanyl was 35 days,
the incremental cost was Euro 338, and the incremental
cost-effectiveness was Euro 9.63. The costs of baseline
treatment, breakthrough and co-medication were higher,
the costs of adverse event treatment were lower with
transdermal fentanyl as compared with sustained mor-
phine. The sensitivity analyses did not greatly affect the
results and showed the model to be quite robust. CON-
CLUSION: Despite a cost-effectiveness ratio higher com-
pared to that of sustained release morphine, transdermal
fentanyl shows a valuable alternative for the treatment of
non-malignant chronic pain. The incremental cost-effec-
tiveness of transdermal fentanyl over sustained release
morphine is quite moderate and justified by its substan-
tially improved effectiveness with good pain control be-
ing a worth on its own, the higher patient preference due
to its simplified and more attractive route of administration.
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THE ATRIAL FIBRILLATION ANTITHROMBOSIS 
MODEL (AFAM): A GENERAL-PURPOSE TOOL 
FOR ANALYSIS, POLICY-MAKING,
AND EDUCATION
Matchar D1, Samsa G1, Sonnenberg F2, Hagerty G2
1Center for Clinical Health Policy Research, Duke University 
Medical Center, Durham, NC, USA; 2UMDNJ Robert Wood 
Johnson Medical School, New Brunswick, NJ, USA
OBJECTIVE: To develop a health and economic simula-
tion model of antithrombosis therapy that would serve as
a general-purpose tool for research planning, clinical trial
analysis, and education, and to demonstrate its use in a
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research planning exercise. METHODS: The Atrial Fi-
brillation Antithrombosis Model (AFAM) provides esti-
mates of health and cost outcomes for up to four compet-
ing, user-defined antithrombosis (AT) strategies that may
be used for individuals with atrial fibrillation (AF). These
include conventional anticoagulation (AC) or enhanced
AT such as improved management of a conventional cou-
marin anticoagulant (e.g., warfarin provided through AC
services) or a new agent with some clinical advantage.
Each strategy is characterized by: (1) patient eligibility
pattern, (2) efficacy, (3) impact on quality of life; (4) dis-
continuation rate; and (5) initial and recurrent cost.
AFAM is based on the Duke Stroke Policy Model (SPM),
a validated natural history simulation that projects the
health and cost outcomes of individuals at risk for stroke
and those who have experienced stroke. As a demonstra-
tion, we applied the model to a research planning exer-
cise. Using AFAM we calculated the threshold efficacy
that would lead to an EAT that is cost-effective (i.e., in-
cremental CE ratio of $50,000.) RESULTS: Assuming
an EAT costs 50% greater than AC, and the relative risk
of stroke for AC is 0.6, then EAT would be cost-effective
if the relative risk for stroke is no less than 0.95. In absolute
terms, a cost-effective EAT would need to reduce annual
stroke risk from 3% down to 2.85%. CONCLUSIONS:
The AFAM takes advantage of a previously developed,
validated natural history simulation model. With relative
ease this can be used to facilitate research planning, trial
analysis and education. Its present application serves to
demonstrate that treatments that are only modestly superior
to existing therapies for stroke prevention can be cost-
effective.
PCV2
POPULATION PROJECTIONS OF 
CARDIOVASCULAR DISEASE MORBIDITY AND 
MORTALITY ASSOCIATED WITH ROFECOXIB’S 
EFFECT ON SYSTOLIC BLOOD PRESSURE
Russell MW, Miller JD, Taylor DCA, Huse DM
ICSL Healthcare Research, Burlington, MA, USA
While cyclöoxygenase-2 inhibitors appear to be safe, hy-
pertensive persons who use rofecoxib may experience in-
creases in systolic blood pressure (SBP). In a randomized
clinical trial involving hypertensive osteoarthritic sub-
jects, use of rofecoxib 25 mg was associated with a 3 mm Hg
increase in systolic blood pressure versus celecoxib 200 mg.
Increased SBP among users of rofecoxib may be associ-
ated with increased risk of cardiovascular disease. OB-
JECTIVE: To estimate excess coronary heart disease
(CHD) and stroke morbidity and mortality associated
with a 3 mm Hg increase in SBP among U.S. adults with
hypertension and osteoarthritis. METHODS: We used
cardiovascular risk prediction models from the Framing-
ham Heart Study and risk factor data from the Third Na-
tional Health and Nutrition Examination Survey to esti-
mate occurrences of CHD and stroke over four years
among osteoarthritic persons with hypertension. We then
estimated the effect of a 3 mm Hg increase in SBP on
event occurrence and costs of cardiovascular disease treat-
ment. RESULTS: An estimated 10.2 million U.S. osteoar-
thritics aged 35 years are hypertensive. Among such
persons, a 3 mm Hg increase in SBP may be associated
with 20,800 additional CHD events (22% fatal) and
21,600 additional stroke events (26% fatal) over four
years. The total cost of treating these events over four
years is estimated to exceed US$650 million in year 2000
constant dollars. CONCLUSION: Increases in SBP asso-
ciated with use of rofecoxib versus celecoxib may trans-
late into significant cardiovascular morbidity and mortal-
ity and impose a sizable economic burden.
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THE COST-EFFECTIVENESS OF TREATING 
CHLAMYDIA PNEUMONIAE INFECTION FOR 
THE PREVENTION OF CORONARY
HEART DISEASE
Sanderson C1, Kubin M2
1London School of Hygiene and Tropical Medicine, London, 
UK; 2Bayer Vital, Leverkusen, Germany
OBJECTIVES: Clinical and epidemiological evidence has
been accumulating for a link between Chlamydia pneu-
moniae and coronary heart disease, but as yet causality is
unproven. The aim of this study was to explore the po-
tential impact and cost-effectiveness of a program of
screening and treatment for C. pneumoniae, assuming a
causal relationship, with a view to informing investment
in definitive trials. METHOD: A spreadsheet model was
used to estimate the impact of different strategies for
screening and treating C. pneumoniae on the incidence of
myocardial infarction and cardiac mortality over a 1-year
post-intervention period, under a range of assumptions.
RESULTS: Screening would potentially be most cost-effec-
tive in patients aged 35 or more with a history of myo-
cardial infarction (central estimate around £3000 per life-
year saved.). Cost-effectiveness will be similar in those
aged 75–84 with established heart disease but no history
of MI, but inferior for younger patients of this kind, and
poorer for people at elevated CHD risk. Sensitivity analy-
sis confirmed that the factors that affect the additional
cost of treatment of survivors of CHD (e.g. length of sur-
vival after prevented death, annual treatment cost for
people with CHD) were all important. The factors that
determine the cost of the screening program (e.g. dura-
tion and daily cost of antibiotic treatment) were also im-
portant, but less so. The results were less sensitive to the
positive predictive value of screening and compliance
with treatment, but these are variables for which wide
ranges of values are plausible. CONCLUSIONS: If cau-
sality of the association between C. pneumoniae and
heart disease were proven, this speculative model sug-
gests that the likely range of costs per life-year saved of a
program of identification and treatment of C. pneumo-
niae targeted at post-MI patients aged 35 or more would
